0001567619-19-000100.txt : 20190102 0001567619-19-000100.hdr.sgml : 20190102 20190102170207 ACCESSION NUMBER: 0001567619-19-000100 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190102 FILED AS OF DATE: 20190102 DATE AS OF CHANGE: 20190102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nanda Nisha CENTRAL INDEX KEY: 0001762683 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36562 FILM NUMBER: 19502437 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Loxo Oncology, Inc. CENTRAL INDEX KEY: 0001581720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462996673 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-653-3880 MAIL ADDRESS: STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06901 3 1 doc1.xml FORM 3 X0206 3 2019-01-02 0 0001581720 Loxo Oncology, Inc. LOXO 0001762683 Nanda Nisha C/O LOXO ONCOLOGY, INC. 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD CT 06901 0 1 0 0 Chief Development Officer Common Stock 18896 D Employee Stock Option (Right to Buy) 1.184 2024-03-03 Common Stock 16983 D Employee Stock Option (Right to Buy) 1.184 2024-03-03 Common Stock 14828 D Employee Stock Option (Right to Buy) 3.648 2024-06-18 Common Stock 4557 D Employee Stock Option (Right to Buy) 13.67 2024-12-18 Common Stock 10861 D Employee Stock Option (Right to Buy) 31.69 2025-12-15 Common Stock 9228 D Employee Stock Option (Right to Buy) 27.00 2026-09-14 Common Stock 14870 D Employee Stock Option (Right to Buy) 26.27 2026-12-05 Common Stock 18375 D Employee Stock Option (Right to Buy) 43.56 2027-03-14 Common Stock 12000 D Employee Stock Option (Right to Buy) 84.88 2028-01-03 Common Stock 75000 D The stock option is fully vested and exercisable. The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 16, 2016, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date. The stock option vests and becomes exercisable as to 1/48th of the total number of shares on October 15, 2016, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date. The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 6, 2017, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date. The stock option vests and becomes exercisable as to 1/48th of the total number of shares on April 15, 2017, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date. The stock option vests and becomes exercisable as to 1/24th of the total number of shares on March 4, 2018, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date. Exhibit List - Exhibit 24.1 - Power of Attorney /s/Jennifer Burstein, by power of attorney 2019-01-02 EX-24.1 2 poa_nanda.htm EXHIBIT LIST - EXHIBIT 24.1 - POWER OF ATTORNEY
POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Jennifer Burstein, Sara Slifka, and Catherine Brady, and each of them, as her true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as a representative of Loxo Oncology, Inc. (the “Company”), any and all Form ID, or Form 3, 4 or 5 reports and any amendments thereto required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules thereunder with respect to transactions in the Company’s securities;
(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, or Form 3, 4 or 5 report and any amendments thereto and timely file such report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney‑in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney‑in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney‑in-fact may approve in his or her discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.  The undersigned acknowledges that no such attorney‑in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys‑in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of December, 2018.


/s/Nisha Nanda 
 Nisha Nanda